Clinical trial · Observational
Metastatic Left Colon and Rectal Cancer Treatment With Anti_EGFR Targeted Therapy
Retrospective Study of Metastatic Left Colon and Rectal Cancer as Regard Treatment With Anti_EGFR Targeted Therapy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Colorectal cancer ranks the second lethal cancer and third prevalent malignant tumour worldwide, Despite of different odern modalities for diagnosis,large number of cases diagnosed at metastatic advanced stage . New treatment approach has been discovered habe been discovered making a huge revolution in metastatic colorectal cancer represented by targeted therapy including anti\_EGFR ,anti\_angiogenic and kinase inhibitors .
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Colorectal Adenocarcinoma | Colorectal Adenocarcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- OS and DFS of patients with metastatic colorectal cancer patients received anti_EGFR targeted therapy
- timeFrame
- Anti_EGFR targeted therapy in assuit university hospitals from 2015 to 2022
- description
- Evaluation of anti-EGFR targeted therapy on metastatic cancer rectum and left colon and factors affecting response to treatment
Secondary outcomes (1)
- measure
- Response rate (RR) in patients received chemotherapy only or with combination with targeted therapy.
- timeFrame
- The response of patients to EGFR targeted therapy in AUH at period from 2015 to 2022
- description
- Factors affecting response to targeted therapy
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. age above 18 2. Both sex 3. Performance status zero to one according to ECOG scale system 4. Histo-pathologial diagnosis adenocarcinoma of left colon or rectum. 5. Patients diagnosed with left colon and rectal cancer. 6. Patients eligible to receive chemotherapy (with renal and liver chemistry, and normal CBC. 7. Patients diagnosed with metastatic stage. 8. K-RAS wild type. Exclusion Criteria: 1. Second malignancy 2. Histo-pathological types other than adenocarcinoma. 3. Right colon cancer patients. 4. Patients refused receiving anti\_EGFR targeted therapy. 5. Patients with any abnormalities preventing to receive chemotherapy. 6. Early stages of colorectal cancer. 7. K-RAS mutant type.
References
Publications (0)
Data not yet available